Ovagen (EDL Tripeptide): ZERO Published Human Clinical Evidence — Bioregulators
Khavinson bioregulator tripeptide (Glu-Asp-Leu) marketed for liver/GI/ovarian support - ZERO peer-reviewed human clinical trials exist.
Overview
CRITICAL EVIDENCE ASSESSMENT: Ovagen (EDL tripeptide, Glu-Asp-Leu, MW 375.37) has ZERO published peer-reviewed human clinical trials despite 40+ years of claimed research. Marketing websites cite a '106 patient clinical study' but NO journal citation, author list, or publication date exists - this study cannot be verified. PubMed search returns zero results for Ovagen/EDL human trials. The EDL tripeptide IS confirmed bioactive (crystallographic evidence of HIV-1 protease inhibition in vitro), but there is NO published evidence for liver, GI, or ovarian effects in humans. Importantly, other Khavinson bioregulators (Epithalamin, Cortexin, Thymalin, Prostatilen) DO have published clinical data - the absence of any Ovagen publications after 40 years is a significant red flag suggesting possible negative or null results that were never published. Same evidence tier as BPC-157 and MOTS-c (zero published human interventional trials). Evidence Quality: 1/5 stars.
Indications
- MARKETED FOR: Liver protection (UNVERIFIED - zero human trials)
- MARKETED FOR: Hepatitis support (UNVERIFIED - zero human trials)
- MARKETED FOR: GI tract health (UNVERIFIED - zero human trials)
- MARKETED FOR: Ovarian health (UNVERIFIED - zero human trials)
- THEORETICAL: Bioregulator gene expression modulation
- NOTE: All claims from vendor websites, NOT peer-reviewed sources
Mechanism of Action
Age-related ovarian function decline, hormonal imbalance, or reproductive stress
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Ovagen | 20 mg | Once daily | Ovarian health maintenance and hormonal support |
| Ovagen | 20 mg | Twice daily for first 2 months, then once daily | For perimenopause or ovarian dysfunction |
Evidence Grade
GRADE C
Safety & Contraindications
- CRITICAL: ZERO published safety studies on Ovagen specifically
- Safety claims come from marketing materials, NOT peer-reviewed research
- General Khavinson bioregulators have good safety record (other compounds, not Ovagen)
- Cannot verify 'no side effects' claims - no published data exists
- Sold as dietary supplement, not pharmaceutical (unregulated)
- Conflict of interest: Developed and sold by same institution (St. Petersburg Institute)
- Contraindicated in hormone-sensitive cancers if used for ovarian claims
- Consult physician before use - completely untested compound in humans